Contra Costa Times Profiles New Research on Products Targeting AIDS Drug Resistance
The Contra Costa Times on Sunday profiled several Bay Area biotechnology companies that are developing new AIDS drugs and tests to fight drug resistance. Celera Diagnostics has developed a genetic test for identifying mutations in HIV that contribute to drug resistance, and the company has applied to the FDA for approval to market the test. In addition, ViroLogic Inc. has developed a test to evaluate a medicine's potency against drug-resistant strains of HIV (Silber, Contra Costa Times, 3/31). The article is available online.
This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
